RBF Capital LLC Makes New Investment in Pediatrix Medical Group, Inc. (NYSE:MD)

RBF Capital LLC purchased a new position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 146,246 shares of the company’s stock, valued at approximately $1,695,000. RBF Capital LLC owned approximately 0.17% of Pediatrix Medical Group at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in MD. nVerses Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at $31,000. Innealta Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at $33,000. Quest Partners LLC raised its holdings in shares of Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after buying an additional 1,524 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of Pediatrix Medical Group in the second quarter valued at about $72,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This represents a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Stock Up 0.5 %

Pediatrix Medical Group stock opened at $14.89 on Thursday. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $16.41. The business has a 50-day moving average of $13.60 and a 200-day moving average of $10.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.29 EPS. As a group, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on MD shares. StockNews.com cut Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Deutsche Bank Aktiengesellschaft lifted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Mizuho lifted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Jefferies Financial Group lifted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Truist Financial boosted their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.